HomeCompareFMBI vs ABBV

FMBI vs ABBV: Dividend Comparison 2026

FMBI yields 82.08% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FMBI wins by $9018859.30M in total portfolio value
10 years
FMBI
FMBI
● Live price
82.08%
Share price
$21.51
Annual div
$17.65
5Y div CAGR
53%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$9018859.41M
Annual income
$8,721,489,002,936.23
Full FMBI calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — FMBI vs ABBV

📍 FMBI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFMBIABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FMBI + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FMBI pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FMBI
Annual income on $10K today (after 15% tax)
$6,976.46/yr
After 10yr DRIP, annual income (after tax)
$7,413,265,652,495.80/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, FMBI beats the other by $7,413,265,631,439.79/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FMBI + ABBV for your $10,000?

FMBI: 50%ABBV: 50%
100% ABBV50/50100% FMBI
Portfolio after 10yr
$4509429.75M
Annual income
$4,360,744,513,853.99/yr
Blended yield
96.70%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

FMBI
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FMBI buys
0
ABBV buys
0
No recent congressional trades found for FMBI or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFMBIABBV
Forward yield82.08%3.06%
Annual dividend / share$17.65$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR53%40.6%
Portfolio after 10y$9018859.41M$102.3K
Annual income after 10y$8,721,489,002,936.23$24,771.77
Total dividends collected$8998503.58M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: FMBI vs ABBV ($10,000, DRIP)

YearFMBI PortfolioFMBI Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$23,258$12,557.63$11,550$430.00+$11.7KFMBI
2$66,648$41,761.97$13,472$627.96+$53.2KFMBI
3$242,436$171,122.79$15,906$926.08+$226.5KFMBI
4$1,149,483$890,076.71$19,071$1,382.55+$1.13MFMBI
5$7,264,442$6,034,495.30$23,302$2,095.81+$7.24MFMBI
6$62,304,564$54,531,610.90$29,150$3,237.93+$62.28MFMBI
7$735,430,944$668,765,060.22$37,536$5,121.41+$735.39MFMBI
8$12,074,554,145$11,287,643,035.07$50,079$8,338.38+$12074.50MFMBI
9$277,916,264,450$264,996,491,515.38$69,753$14,065.80+$277916.19MFMBI
10$9,018,859,405,898$8,721,489,002,936.23$102,337$24,771.77+$9018859.30MFMBI

FMBI vs ABBV: Complete Analysis 2026

FMBIStock

First Midwest Bancorp, Inc. operates as the bank holding company for First Midwest Bank that provides various banking products and services. The company accepts checking, NOW, money market, and savings accounts, as well as various types of short-term and long-term certificates of deposit. Its loan products include working capital needs; accounts receivable financing; inventory and equipment financing; sector-based lending, including healthcare, asset-based lending, structured finance, and syndications; agricultural loans; and mortgages, home equity lines and loans, personal loans, specialty loans, and consumer secured and unsecured loans, as well as funding for the construction, purchase, refinance, or improvement of commercial real estate properties. In addition, the company offers treasury management products and services comprising automated clearing house collection, lockbox, remote deposit capture, and financial electronic data interchange; wire transfer, account reconciliation, controlled disbursement, direct deposit, and positive pay services; information reporting services; corporate credit cards; and liquidity management, fraud prevention, and merchant services. Further, it provides fiduciary and executor, financial planning, investment advisory, employee benefit plan, and private banking services to corporate and public retirement plans, foundations and endowments, high net worth individuals, and multi-employer trust funds. Additionally, the company offers debit and automated teller machine (ATM), and credit cards; internet and mobile, and telephone banking services; and financial education services. The company operates 115 locations and 184 ATMs in metropolitan Chicago, southeast Wisconsin, northwest Indiana, central and western Illinois, eastern Iowa, and other markets in the Midwest. First Midwest Bancorp, Inc. was incorporated in 1982 and is headquartered in Chicago, Illinois.

Full FMBI Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this FMBI vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FMBI vs SCHDFMBI vs JEPIFMBI vs OFMBI vs KOFMBI vs MAINFMBI vs JNJFMBI vs MRKFMBI vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.